Navigation Links
Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
Date:2/6/2008

SOUTH SAN FRANCISCO, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that George A. Scangos, Ph.D., president and chief executive officer of Exelixis, will present at the 10th Annual BIO CEO and Investor Conference at 2:45 p.m. ET / 11:45 a.m. PT on Tuesday, February 12, 2008.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...AMBRIDGE, Mass., Dec. 2 TechConnec... technology development and product integration in...the December 11th deadline for technology abstract...h year, TechConnect World, in association with the... the Clean Technology and Sustainable Industries O...
(Date:12/2/2009)...NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcer...) (NYSE: SCR ), a leading pharmaceutical company...nd marketing of branded,generic and proprietary ph...f,its drugs have been included in China,s National...d by China,s Ministry of Human Resources and Socia...
(Date:12/2/2009)...N, N.J., Dec. 2 According to the N...ent of Americans diagnosed with diabetes already h...retinopathy, damage to the retina caused by leaky ...ople with diabetes and is one of the most feared d...of all patients who,ve had diabetes for 10 years o...
(Date:12/1/2009)...EW YORK, Dec. 1 Reportlinker.com a...lable in its catalogue: ,, Industrial Enzymes ...linker.com/p0164431/Industrial-Enzymes---A-Global-...t is an oligopoly with few strong players and a ho...vities. Keen competition and commoditization chara...
Breaking Biology Technology:Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10
...- Collaboration will utilize Firmenich,s world lea... flavor ingredients, - New S2383 flavor enhancer m... healthcare products to reduce the need for suc...vember 6, 2008, Senomyx, Inc. (Nasdaq: SNMX ), a ...ologies to discover and develop novel,flavor ingre...
...Recent Accomplishments Include:, - Receipt of GRAS...cralose, Enhancer S2383, which allows commerciali...ion with Firmenich SA for commercialization of S23...ulatory filings for Sucrose (...lestone in collaboration with Solae to develop bit...
...NOVATO, Calif., Nov. 6 BioMarin,Pharmaceutical In... clinical,studies of Kuvan(R) (sapropterin dihydro...placement therapies for MPS IVA (Morquio,Syndrome)...nnual Meeting of,the American Society of Human Gen...r 11-15, 2008., "We look forward to a number of p...
Other Biology Technology:SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 14Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 2Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 3
(Date:12/4/2009)...otal gene activity in organs relevant for coronary...edical university Karolinska Institutet have ident...recruitment of white blood cells into the atherosc...ished in the open-access journal PLoS Genetics , ...d cells in the development of atherosclerosis may ...
(Date:12/4/2009)...logram (EEG) is widely used by physicians and scie...rological disorders. However, it has remained larg...e an exact view of what is happening inside the br...ological Cybernetics in Tbingen, Germany, have now...ed within the brain to that measured with EEG. The...
(Date:12/4/2009)...atical model of heart cells, University of Iowa in...l enzyme, calmodulin kinase II (CaM kinase), disru...The study, which also involved Columbia University... Computational Biology . , "Recently, researche...ase II as a critical regulator of the heart,s resp...
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2How to read brain activity? 2U-Iowa study helps advance heart-related research 2Sebastian Ferrero Foundation to Host 2nd Annual Fundraiser Noche de Gala 54555 1Sebastian Ferrero Foundation to Host 2nd Annual Fundraiser Noche de Gala 54555 2Sebastian Ferrero Foundation to Host 2nd Annual Fundraiser Noche de Gala 54555 3Sebastian Ferrero Foundation to Host 2nd Annual Fundraiser Noche de Gala 54555 4Sebastian Ferrero Foundation to Host 2nd Annual Fundraiser Noche de Gala 54555 5Low Choline Level in Pregnancy Tied to Birth Defects 54551 1UC Davis 3A Cash for Clunkers program is expensive way to cut carbon emissions 9579 1
...Studying the parasite that causes African sleeping...ered a previously unknown way of making fatty acid...ells. The find unveils more about the biology of t...et for designing new drugs to fight the illness th...a year worldwide. , Results of the study, in the ...
...The recovery of biodiversity after the end-Cretace...viously thought, according to paleontologists. New...laces, plant and insect diversity were severely ou...tinction took place 65.5 million years ago. Labele...e Cenozoic Era and the Paleocene Epoch. , "The K-...
...For the first time, researchers have developed a w...rasfonin in enough quantity to learn how it works....e walls of a New Zealand cave, the chemical tricks...ealthy cells untouched. , "In 2000, scientists in...me tremendous potential as a prototype anticancer ...
Other Biology News:African parasite makes component of fat differently from all other organisms 2African parasite makes component of fat differently from all other organisms 3Insect predation sheds light on food web recovery after the dinosaur extinction 2Insect predation sheds light on food web recovery after the dinosaur extinction 3Insect predation sheds light on food web recovery after the dinosaur extinction 4New lab technique churns out fungus' potential cancer fighter 2
Rabbit Anti-Human DNase II Polyclonal Antibody, Unconjugated from Calbiochem
BD BioCoat Vented Caps for 175 cm2 Flasks from BD Biosciences - Discovery Labware
GC-RICH PCR System from Roche Applied Science
Anti-I-Ab MHC Class II Monoclonal Antibody, FITC Conjugated, Clone 28-16-8S from Beckman Coulter
Biology Products: